Experiments on Laser Mediated Photosensitization: Preclinical Evaluation of Mono-1-Aspartyl Chlorin e6 (NPe6)

  • A. Ferrario
  • C. J. Gomer
Part of the NATO ASI Series book series (NSSB, volume 252)


A renewed interest in the synthesis and evaluation of “second generation” photosensitizers for use in PDT has developed due to the several photophysical restrictions of Photofrin II. Photofrin II is a poorly defined mixture of monomeric and aggregated porphyrins and has extremely weak absorption at wavelengths above 600 nm (where light transmission through tissue is greatest). In addition the drug is retained in numerous normal tissues (such as skin) for extended periods of time. Photosensitizers with preferential tumor tissue retention, rapid clearance from normal tissues, increased extinction coefficients and absorption peaks shifted to higher wavelengths, should allow for greater utilization of delivered light which has improved tissues transmission properties.


Light Treatment Light Dose Preclinical Evaluation Follow Drug Administration Tumor Cure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    C. J. Gomer and A. Ferrario, “Tissue distribution and photosensitizing properties of mono-1-aspartyl chlorin e6 (NPe6) in a mouse tumor model”, accepted for publication Cancer Res. (1990)Google Scholar
  2. 2.
    D. A. Bellnier, Y.-K. Ho, R. K. Pandey, J. R. Missert and T. J. Dougherty, “Distribution and elimination of Photofrin II in mice”, Photochem. Photobiol. 50:221 (1989)CrossRefGoogle Scholar
  3. 3.
    D. Kessel, personal communication.Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • A. Ferrario
    • 1
  • C. J. Gomer
    • 1
  1. 1.Childrens Hospital of Los AngelesUniversity of Southern California School of MedicineLos AngelesUSA

Personalised recommendations